AG-221 bei fortgeschrittener AML mit IDH2 Mutation in älteren Patienten (#623)
Laufzeit: 01.01.2017 - 31.12.2019
imported
Kurzfassung
A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage Acute Myeloid Leukemia harboring an Isocitrate Dehydrogenase 2 mutation
